Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination drug is a multi-ingredient pharmaceutical product used for the symptomatic relief of the common cold and influenza. It consists of three primary active small molecules: **paracetamol** (acetaminophen), **caffeine**, and **chlorpheniramine**. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis, primarily within the central nervous system. Caffeine is included as a central nervous system stimulant to enhance the analgesic efficacy of paracetamol and to mitigate the sedative effects often associated with antihistamines. Chlorpheniramine is a first-generation H1-receptor antagonist that effectively reduces allergic-type symptoms such as rhinorrhea, sneezing, and watery eyes. Developed and manufactured by Jilin Province Oriental Pharmaceutical, this oral formulation is indicated for treating fever, headache, sore throat, and nasal congestion associated with upper respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + caffeine + chlorpheniramine.